Topic hub · Timeline updated 25 September 2026
The complete record of America’s most consequential drug-policy fight. From the Controlled Substances Act in 1970 to Schedule III: the petitions, hearings, executive orders, court fights and market reaction, in one place.
Where it stands · June 2026
Three parallel court challenges — from Republican state AGs, prohibitionist groups, and pharmaceutical petitioners — are now seeking to derail it.
Read the latest→What happens next · June 2026
A pivotal administrative hearing on 29 June 2026 will determine whether rescheduling extends to recreational cannabis.
Meanwhile, Treasury and IRS guidance on 280E relief remains outstanding five weeks after announcement.
Latest reporting: DEA Issues First Federal Registrations to 900 Dispensaries, But Dual-Licence States Remain Uncertain→The brief
Cannabis rescheduling would move marijuana from Schedule I to Schedule III under the Controlled Substances Act, ending a half-century classification alongside heroin and LSD. The shift would unlock 280E tax relief for cannabis operators, accelerate medical research, and reshape capital markets — but the path from DEA hearings to final rule has been anything but linear.
This hub is the definitive record — from the 1970 Controlled Substances Act and three failed rescheduling petitions, through Judge Francis Young’s overruled 1988 ruling and a half-century of administrative resistance, to the modern DEA hearings, executive orders and market reaction.
1970–2026 in 6 phases and 30 events. Select a phase to see its events. Updated 25 September 2026.
Showing 30 events from all phases, newest first
Three parallel court challenges — from Republican state attorneys general (Nebraska, Indiana, Louisiana), prohibitionist groups (SAM, NDASA), and a pharmaceutical coalition led by MMJ International — converge ahead of the critical 29 June hearing on extending rescheduling to recreational cannabis.
Why Schedule III is the start of the next battle — 280E reform, banking, interstate commerce, and federal legalisation.
The headline moment, with the consequential nuances behind the word “partly”.
An executive order moving cannabis to Schedule III is signed — opening a new phase of the fight.
Reports surface that agencies across the federal government are preparing for an imminent rescheduling announcement.
The rescheduling decision is placed firmly in the hands of a new permanent administrator.
Half a year after temporary suspension, the rescheduling process has produced no measurable advance.
Procedural conflict between the DEA and other participants forces the hearing into delay.
The opening day of the rescheduling hearing — and the first procedural skirmishes between participants.
A six-week hearing schedule is announced as frustrations with DEA process continue to build.
Donald Trump’s return to the White House throws the future of the rule into uncertainty. Industry observers shift focus to the incoming administration’s appointees.
The agency pushes formal hearings past the US election — making the outcome politically contingent on the next administration.
The administration walks back earlier confidence on the timeline. Investor sentiment wavers.
DEA Administrator Anne Milgram refers the rule to an ALJ for formal hearing — a procedural step that delays the rule and opens the door to witness disputes.
More than 90% of the ~43,000 public comments support rescheduling, with the majority calling for further reform beyond Schedule III.
Attorney General Merrick Garland signs the Notice of Proposed Rulemaking. The Federal Register publishes the proposal and opens a 60-day public comment window.
The full HHS/FDA review document — the basis for the Schedule III recommendation — is released, revealing the federal government’s evidence that cannabis has accepted medical use.
The Department of Health and Human Services formally recommends to the DEA that cannabis be moved to Schedule III. The recommendation becomes public, exposing the federal government’s own scientific case for reform.
President Biden directs HHS and the DOJ to review cannabis scheduling, and pardons federal simple-possession offences. It is the first executive action toward rescheduling in the CSA’s 52-year history.
The 2018 Farm Bill federally deschedules hemp (cannabis with under 0.3% THC) — establishing the regulatory precedent that not all cannabis must sit in Schedule I.
The DEA rejects rescheduling petitions filed by the governors of Rhode Island and Washington. It is the last formal denial before the modern process begins.
The D.C. Circuit upholds the DEA in Americans for Safe Access v. DEA, leaving the Schedule I designation intact through the courts.
The DEA rejects the Coalition’s petition, ruling that cannabis has no accepted medical use — even as 16 US states already operate medical cannabis programmes.
Americans for Safe Access and partners file the third major rescheduling petition. The DEA takes nine years to respond.
Researcher Jon Gettman files a fresh rescheduling petition. The DEA takes six years to deny it.
DEA Administrator John Lawn formally rejects the rescheduling recommendation. Appeals continue through 1994, when the D.C. Circuit upholds the DEA and the original NORML petition is finally exhausted.
Administrative Law Judge Francis Young rules cannabis “one of the safest therapeutically active substances known to man” and recommends moving it out of Schedule I. The DEA Administrator overrules him.
The National Organization for the Reform of Marijuana Laws files the first formal petition to reschedule cannabis. It begins a 22-year administrative battle.
The National Commission on Marihuana and Drug Abuse — appointed by Nixon — concludes cannabis should be decriminalised for personal use. Nixon rejects the report’s findings and shelves it.
Congress passes the CSA. Cannabis is placed in Schedule I — a “temporary” classification pending the findings of a presidential commission.
IRC Section 280E prevents cannabis operators from deducting ordinary business expenses. Moving to Schedule III would end it for plant-touching operators, but relief depends on Treasury and IRS guidance.
Rescheduling moves cannabis to a different category within the Controlled Substances Act. Recreational cannabis would remain federally controlled; legalisation would require an act of Congress.
Schedule III is the start of the next battle, not the end: banking access, interstate commerce and federal legalisation all remain open questions.
Republican lawmakers have introduced legislation to block 280E relief even if cannabis is rescheduled, spending bills have targeted the process, and the administrative route is subject to legal challenge.
Our coverage, organised by the four fronts of the fight
Lawsuits, witness disputes, allegations of bias and a steady stream of procedural delays.
15 stories ↓02 · Politics & the White HouseExecutive orders, spending bills designed to derail the process, and the lobbying surge.
14 stories ↓03 · Markets, M&A & capitalThe volatility, the 280E implications and what serious capital is actually doing.
10 stories ↓04 · Industry reaction & outlookCautious optimism, strategic positioning and structural scepticism, on the record.
8 stories ↓01 · The DEA & legal process
The DEA's handling of cannabis rescheduling has produced lawsuits, witness disputes, allegations of bias, and a steady stream of procedural delays. This is the inside record of how the agency has shaped — and slowed — the process.
02 · Politics & the White House
From executive orders to congressional spending bills designed to derail the process, rescheduling is now an open political fight. We track the partisan moves, the lobbying surge, and the strategic calculations on both sides of the aisle.
03 · Markets, M&A & capital
Every rescheduling rumour has produced a price reaction. We trace the volatility, the 280E implications, the M&A wave, and what serious capital allocators are actually doing while public markets oscillate between euphoria and despair.
04 · Industry reaction & outlook
Inside the industry, the response to rescheduling has split between cautious optimism, strategic positioning, and structural scepticism. We round up the on-the-record reaction, the European read, and the operators preparing for whatever comes next.
Live from stories tagged rescheduling (116) · See all
Cannabis rescheduling refers to the process of moving marijuana from Schedule I to Schedule III under the US Controlled Substances Act. Schedule I is reserved for substances the federal government considers to have no accepted medical use and a high potential for abuse — a category that has historically included heroin and LSD. Schedule III covers substances with accepted medical uses and a moderate-to-low potential for dependence.
The reclassification would not legalise cannabis federally, but it would meaningfully change how it is regulated, taxed and researched.
Movement on rescheduling has occurred — including executive action and DEA hearings — but the process has been marked by delays, witness disputes and political resistance. The current state is best described as actively contested: parts of the federal government have moved, others have not, and the rule's full effect on operators is still being worked through.
For the most up-to-date status, see The US Officially Reschedules Cannabis — Partly and The Fight Is Far From Over.
The single biggest commercial impact of moving to Schedule III is the end of IRC Section 280E, the tax provision that prevents cannabis operators from deducting ordinary business expenses. Removing 280E would materially improve cash flow for nearly every plant-touching operator, particularly multi-state operators (MSOs) carrying heavy effective tax burdens.
Beyond tax, rescheduling would expand legal research access, change the calculus around banking, and reshape investor sentiment toward the sector. See our reporting on the MSO tax exposure.
No. Rescheduling moves cannabis to a different category within the Controlled Substances Act — it does not legalise cannabis at the federal level. Recreational cannabis would remain federally controlled, and existing state markets would continue to operate within their own legal frameworks. Federal legalisation would require an act of Congress, not an administrative rescheduling.
The DEA's rulemaking process has been delayed by witness disputes, lawsuits, allegations of agency bias, leadership changes, and political pressure from Capitol Hill. Multiple participants have challenged the DEA's conduct — and the agency itself has navigated subpoena requests, hearing reschedules and a change in administrator. See our DEA & Legal Process coverage for the full chronology.
Cannabis equities have moved sharply on every major rescheduling signal — rallying on positive announcements and selling off on delays. The pattern is now well-established enough that some analysts characterise rescheduling-driven moves as their own discrete trading regime.
For ongoing market reaction, see our Cannabis Stocks Tracker.
Yes — and political opposition has explicitly sought to do so. Republican lawmakers have introduced legislation to block 280E relief even if cannabis is rescheduled, and US spending bills have included provisions targeting funding for the rescheduling process. The administrative pathway is also subject to legal challenge. Anyone modelling the impact of rescheduling needs to account for the realistic possibility of partial rollback.
As of June 2026, formal Treasury and IRS implementation guidance on 280E relief remained outstanding — five weeks after the rescheduling rule was announced. Seven House Democrats wrote to the IRS on 28 May urging the agency to publish guidance, citing the three-year statutory window that limits operators' ability to amend prior returns and claim refunds for overpaid tax.
Until guidance lands, plant-touching operators face uncertainty on the timing and scope of refund claims for prior years.
US rescheduling has outsized influence on international markets — both because of US capital flows and because it shapes the regulatory model other countries reference. European operators, in particular, have begun to rethink US strategy in response. See our Cannabis Europa London 2026 preview.
